Objectif
Anaemia is the most common pathological condition affecting 1.6 billion individuals worldwide. It thus presents a serious health care problem and an economic burden. Reduction in red blood cell (RBC) number can be caused by blood loss, diet, stress conditions including endurance sport, and pathologies which are caused by primary genetic aberrations or are secondary to the malfunction of other cell types. Transfusion of RBC, which is often the only cure for severe cases of anaemia, is associated with risks such as thrombosis and transfusion reactions due to allo-immunisation. There is an unmet need to improve treatment of anaemia through early and accurate diagnosis, targeted treatment, and increased safety and effectiveness of RBC transfusion. The aim of RELEVANCE is to improve fast and cost-effective diagnosis of the underlying cause of primary anaemia, and to improve treatment options for both general and personalised medicine. We defined five key objectives: (1) to improve diagnostics of anaemia, particularly for hereditary rare forms of anaemia (RA); (2) to find novel treatments for anaemia that target RBC production, ageing and clearance; (3) to reduce premature loss of RBC following transfusion; (4) to produce cultured RBC for transfusion; (5) to monitor and optimise RBC function during sport and exercise. RELEVANCE will train 15 early stage researchers (ESR) at four SMEs and eight academic partners, two of whom are at blood supply centres and two are diagnostic centres for RA. The continuous interactions between the clinic, blood supply centers, basic research, and industry will select for the most relevant unmet medical needs, and will stimulate innovative procedures that are immediately probed for applicability and validity both in a research and a clinical setting. RELEVANCE will organize three open access summer schools, extending training beyond the ESR of the ITN sustaining the critical number of young talented professionals in the field.
Champ scientifique
- medical and health sciencesclinical medicineangiologyvascular diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesbasic medicinepathology
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesclinical medicinehematology
Mots‑clés
Programme(s)
Régime de financement
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinateur
8006 Zurich
Suisse
Voir sur la carte
Participants (13)
66123 Saarbrucken
Voir sur la carte
BS8 1QU Bristol
Voir sur la carte
27100 Pavia
Voir sur la carte
1006 AN Amsterdam
Voir sur la carte
3584 CX Utrecht
Voir sur la carte
Participation terminée
08036 Barcelona
Voir sur la carte
75654 Paris
Voir sur la carte
75794 Paris
Voir sur la carte
85716 UNTERSCHLEISSHEIM
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
TS10 5SQ REDCAR
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
80339 Munchen
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
2000 Frederiksberg
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
08916 Badalona
Voir sur la carte
Partenaires (2)
Les organisations partenaires contribuent à la mise en œuvre de l’action, mais ne signent pas la convention de subvention.
Homburg
Voir sur la carte
Les organisations partenaires contribuent à la mise en œuvre de l’action, mais ne signent pas la convention de subvention.
66386 St Ingbert
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.